An Open Label, Phase I, Dose Escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Doses of BI 836909 in Relapsed and/or Refractory Multiple Myeloma Patients
Phase of Trial: Phase I
Latest Information Update: 13 Jun 2017
At a glance
- Drugs BI 836909 (Primary) ; BI 836909 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; First in man
- Sponsors Boehringer Ingelheim
- 07 Jun 2017 Planned End Date changed from 31 Dec 2017 to 28 Sep 2018.
- 07 Jun 2017 Planned primary completion date changed from 31 Jul 2017 to 30 Jul 2018.
- 19 Sep 2016 Planned number of patients changed from 120 to 50.